No Data
No Data
We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Pharvaris Price Target Maintained With a $55.00/Share by Citizens Capital Markets
Pharvaris Reports Sustained Reduction in HAE Attack Rates and Improved Quality of Life Across Long-Term Deucrictibant Studies
Pharvaris Reports Safety and Efficacy Data of Deucrictibant
Pharvaris Showcases Phase 3 Data on Deucrictibant for Hereditary Angioedema at AAAAI-WAO Congress
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025